血小板因子4(PF4)及其在疾病中的多重作用

IF 6.9 2区 医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2024-03-01 DOI:10.1016/j.blre.2023.101155
Zhiyan Liu , Longtu Li , Hanxu Zhang , Xiaocong Pang , Zhiwei Qiu , Qian Xiang , Yimin Cui
{"title":"血小板因子4(PF4)及其在疾病中的多重作用","authors":"Zhiyan Liu ,&nbsp;Longtu Li ,&nbsp;Hanxu Zhang ,&nbsp;Xiaocong Pang ,&nbsp;Zhiwei Qiu ,&nbsp;Qian Xiang ,&nbsp;Yimin Cui","doi":"10.1016/j.blre.2023.101155","DOIUrl":null,"url":null,"abstract":"<div><p><span>Platelet factor 4 (PF4) combines with heparin to form an antigen that could produce </span>IgG antibodies<span> and participate in heparin-induced thrombocytopenia<span> (HIT). PF4 has attracted wide attention due to its role in novel coronavirus<span><span><span> vaccine-19 (COVID-9)-induced immune thrombotic thrombocytopenia (VITT) and </span>cognitive impairments<span><span>. The electrostatic interaction between PF4 and negatively charged molecules is vital in the progression of VITT, which is similar to HIT. Emerging evidence suggests its multiple roles in hematopoietic and angiogenic inhibition, platelet coagulation interference, host inflammatory response promotion, vascular inhibition, and antitumor properties. The emerging pharmacological effects of PF4 may help deepen the exploration of its mechanism, thus accelerating the development of targeted therapies. However, due to its pleiotropic properties, the development of </span>drugs targeting PF4 is at an early stage and faces many challenges. Herein, we discussed the characteristics and </span></span>biological functions<span> of PF4, summarized PF4-mediated signaling pathways<span>, and discussed its multiple roles in diseases to inform novel approaches for successful clinical translational research.</span></span></span></span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Platelet factor 4(PF4) and its multiple roles in diseases\",\"authors\":\"Zhiyan Liu ,&nbsp;Longtu Li ,&nbsp;Hanxu Zhang ,&nbsp;Xiaocong Pang ,&nbsp;Zhiwei Qiu ,&nbsp;Qian Xiang ,&nbsp;Yimin Cui\",\"doi\":\"10.1016/j.blre.2023.101155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Platelet factor 4 (PF4) combines with heparin to form an antigen that could produce </span>IgG antibodies<span> and participate in heparin-induced thrombocytopenia<span> (HIT). PF4 has attracted wide attention due to its role in novel coronavirus<span><span><span> vaccine-19 (COVID-9)-induced immune thrombotic thrombocytopenia (VITT) and </span>cognitive impairments<span><span>. The electrostatic interaction between PF4 and negatively charged molecules is vital in the progression of VITT, which is similar to HIT. Emerging evidence suggests its multiple roles in hematopoietic and angiogenic inhibition, platelet coagulation interference, host inflammatory response promotion, vascular inhibition, and antitumor properties. The emerging pharmacological effects of PF4 may help deepen the exploration of its mechanism, thus accelerating the development of targeted therapies. However, due to its pleiotropic properties, the development of </span>drugs targeting PF4 is at an early stage and faces many challenges. Herein, we discussed the characteristics and </span></span>biological functions<span> of PF4, summarized PF4-mediated signaling pathways<span>, and discussed its multiple roles in diseases to inform novel approaches for successful clinical translational research.</span></span></span></span></span></p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23001224\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23001224","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

血小板因子4 (PF4)与肝素结合形成抗原,可产生IgG抗体,参与肝素诱导的血小板减少症(HIT)。PF4因其在新型冠状病毒疫苗-19 (COVID-9)诱导的免疫性血栓性血小板减少症(VITT)和认知障碍中的作用而受到广泛关注。PF4与带负电荷分子之间的静电相互作用在VITT的发展过程中起着至关重要的作用,这与HIT类似。越来越多的证据表明,它在抑制造血和血管生成、干扰血小板凝固、促进宿主炎症反应、抑制血管和抗肿瘤等方面具有多种作用。PF4的新药理作用可能有助于加深对其机制的探索,从而加速靶向治疗的发展。然而,由于其多效性,针对PF4的药物开发尚处于早期阶段,面临诸多挑战。在此,我们讨论了PF4的特性和生物学功能,总结了PF4介导的信号通路,并讨论了它在疾病中的多重作用,为成功的临床转化研究提供了新的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Platelet factor 4(PF4) and its multiple roles in diseases

Platelet factor 4 (PF4) combines with heparin to form an antigen that could produce IgG antibodies and participate in heparin-induced thrombocytopenia (HIT). PF4 has attracted wide attention due to its role in novel coronavirus vaccine-19 (COVID-9)-induced immune thrombotic thrombocytopenia (VITT) and cognitive impairments. The electrostatic interaction between PF4 and negatively charged molecules is vital in the progression of VITT, which is similar to HIT. Emerging evidence suggests its multiple roles in hematopoietic and angiogenic inhibition, platelet coagulation interference, host inflammatory response promotion, vascular inhibition, and antitumor properties. The emerging pharmacological effects of PF4 may help deepen the exploration of its mechanism, thus accelerating the development of targeted therapies. However, due to its pleiotropic properties, the development of drugs targeting PF4 is at an early stage and faces many challenges. Herein, we discussed the characteristics and biological functions of PF4, summarized PF4-mediated signaling pathways, and discussed its multiple roles in diseases to inform novel approaches for successful clinical translational research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
期刊最新文献
From MGUS to multiple myeloma: Unraveling the unknown of precursor states. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies. Corrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1